Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB19055 dose-ranging Phase II trial in uncontrolled and refractory hypertension
ChiCTR2600129811Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VB19055 in hypertension (HTN) (4 arms), sponsored by Ruijin Hospital. Primary endpoint: Sitting systolic blood pressure. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
VB19055
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2600129811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129811.